Last reviewed · How we verify
NCT03142217: Huntington
Characterization of the Profile of Dysarthria in Huntington's Disease, Using the Clinical Evaluation Battery of Dysarthria
NA trial testing Study of dysarthria in patients with Huntington's disease in Dysarthria. Withdrawn.
1 March 2017
Quick facts
| Lead sponsor | Centre Hospitalier Universitaire, Amiens |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Start date | 26 March 2015 |
| Primary completion | 1 March 2017 |
| Estimated completion | 1 March 2017 |
Drugs / interventions tested
- Study of dysarthria in patients with Huntington's disease
Conditions studied
- Dysarthria — all drugs for Dysarthria →
- Huntington Disease — all drugs for Huntington Disease →
Sponsor
Centre Hospitalier Universitaire, Amiens
Who can join
18 and older, any sex, with Dysarthria or Huntington Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Huntington's disease is a hereditary disease of rare autosomal dominant transmission, both neurodegenerative and neuro-psychiatric. Clinically, there are motor symptoms (chorea), cognitive disorders (dementia) and psychiatric disorders. Among motor disorders, dysarthria is a commonly found symptom. This is classically referred to as hyperkinetic dysarthria according to the criteria of Darley's classification. However, this old classification (1969) is only based on perceptual analysis and lack of specificity. Moreover, in the course of the disease, chorea (control of the striatal attack D2) decreases to give place to a parkinsonian syndrome (control of the striatal attack D1) and the dysarthria also evolves towards a hypokinetic form . It also seems likely that cerebellar involvement (responsible for ataxia) contributes to dysarthria. No studies have been published to date to characterize dysarthria in Huntington's disease in a quantified, objective and specific manner. However, Canan Ozsancak describes choreic dysarthria as heterogeneous according to the patients and variable according to the productions. A perceptual study reports an imprecision of the consonants, a lengthening of the pauses, a variable flow, an absence of modulation of the pitch and a hoarse voice. Finally, few patients are cared for in speech therapy and there is no specific rehabilitation strategy: this would require - and justify a more precise study of the dysarthria of these patients. The Clinical Evaluation of Dysarthria developed by Pascal Auzou and Véronique Rolland-Monnoury is a recent and partially standardized tool, combining qualitative and quantitative evaluation, which seems adapted to try to better characterize the dysarthria in Huntington's disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03142217
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dysarthria
Currently open trials in the same condition.
- NCT07460037 — Chinese-Specific Speech Imagery Coding Using High-Density ECoG · NA · recruiting
- NCT07435155 — ACURES: Acoustic and Respiratory Parameters for Dysarthria Assessment · recruiting
- NCT07129291 — Development of Dual Language (Urdu and English) Digital Software for SA, Management Of Adult Dysarthria · NA · active not recruiting
- NCT06593860 — Dysarthria Management for Minor Groups · NA · recruiting
- NCT06094205 — Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02) · NA · recruiting
Other Centre Hospitalier Universitaire, Amiens trials
Trials by the same sponsor.
- NCT07354568 — Prognosis of Patients With Mixed Cardiogenic-Vasoplegic Shock · recruiting
- NCT07071662 — Induction of Labor in Breech Presentation · completed
- NCT06909487 — Clinical Characterization of Very and Extremely Preterm Infants Who Received Excess Erythrocyte Transfusions With Respec · completed
- NCT07037719 — Automatic Detection of Eligible Patients to RAUC Protocol (RAUCISABLE) · recruiting
- NCT06996145 — Study of the Isometry of the Anterior Cruciate Ligament From the Center of the Native MRI Insertion Reported on Dynamic · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03142217 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire, Amiens
- Last refreshed: 5 May 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03142217.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing